Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Immunoglobulin A Nephropathy: full-pipeline trial registry
5 of 14 indexed Immunoglobulin A Nephropathy trials are currently recruiting.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 5 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Immunoglobulin A Nephropathy: 14 US clinical trials tracked, 5 recruiting.
Immunoglobulin A Nephropathy is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Travere Therapeutics, running 4 of these trials.
Enrollment posture brief
Registry condition immunoglobulin-a-nephropathy
OPEN 5 | RECR 36% | LATE 7 | EARLY 5 | RANK #1230 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Attention (36% recruiting · 14 trials)
Immunoglobulin A Nephropathy lists 5 open slots (36% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Immunoglobulin A Nephropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Immunoglobulin A Nephropathy is recruiting below its size-band peers.
5 of 14 indexed trials (35.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Immunoglobulin A Nephropathy research.
Travere Therapeutics accounts for 4 of 14 trials (28.6%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Immunoglobulin A Nephropathy enrolment sits around 383 participants.
Median target enrolment is 383 among the 14 trials that report a genuine target (sentinel values excluded). 5 of those (35.7%) plan for fewer than 100 participants.
-
Immunoglobulin A Nephropathy research is mostly interventional.
12 interventional and 2 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Alexion Pharmaceuticals
NCT06291376
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Novartis Pharmaceuticals
NCT06952426
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Travere Therapeutics
NCT05003986
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Alexion Pharmaceuticals
NCT07024563
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Novartis Pharmaceuticals
NCT06797518
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
Alpine Immune Sciences Inc, A Subsidiary of Vertex
NCT06564142
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization
NCT05248646
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Travere Therapeutics
NCT03762850
Atrasentan in Patients With IgA Nephropathy
Chinook Therapeutics
NCT04573478
A Study of Zigakibart in Adults With IgA Nephropathy
Novartis Pharmaceuticals
NCT05852938
Atrasentan in Patients With Proteinuric Glomerular Diseases
Novartis Pharmaceuticals
NCT04573920
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Alpine Immune Sciences
NCT05732402
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
Travere Therapeutics
NCT05200871
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Travere Therapeutics
NCT05856760
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Immunoglobulin A Nephropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Immunoglobulin A Nephropathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Immunoglobulin A Nephropathy page
14 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Immunoglobulin A Nephropathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Travere Therapeutics sponsors the most Immunoglobulin A Nephropathy trials on record, review their full trial history before evaluating a specific study. See Travere Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Immunoglobulin A Nephropathy condition card totals 14 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.